Stock Analysis on Net

Thermo Fisher Scientific Inc. (NYSE:TMO)

$24.99

Analysis of Profitability Ratios
Quarterly Data

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Profitability Ratios (Summary)

Thermo Fisher Scientific Inc., profitability ratios (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 27, 2025 Jun 28, 2025 Mar 29, 2025 Dec 31, 2024 Sep 28, 2024 Jun 29, 2024 Mar 30, 2024 Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022
Return on Sales
Gross profit margin
Operating profit margin
Net profit margin
Return on Investment
Return on equity (ROE)
Return on assets (ROA)

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).


The profitability metrics exhibited consistent trends over the observed period. Generally, margins and returns experienced a decline from early 2022 through 2023, followed by a period of stabilization and modest improvement through early 2025. The most recent quarter indicates a slight pullback in some metrics.

Gross Profit Margin
The gross profit margin demonstrated a clear downward trajectory from 48.37% in April 2022 to a low of 39.75% in July 2023. Subsequently, the margin stabilized and showed incremental gains, peaking at 41.34% in March 2025. The latest reading, June 2025, shows a slight decrease to 41.18%, but remains above the lows experienced in 2023.
Operating Profit Margin
Similar to the gross profit margin, the operating profit margin decreased from 23.83% in April 2022 to 15.42% in July 2023. A recovery phase began, with the margin reaching 17.38% in December 2025. This recovery, however, was less pronounced than that of the gross profit margin, and the latest value of 17.16% in September 2025 represents a slight decline from the recent peak.
Net Profit Margin
The net profit margin followed the same general pattern as the other margins, declining from 18.49% in April 2022 to 13.14% in July 2023. It then increased, reaching 15.23% in March 2025, before decreasing slightly to 15.02% in September 2025. The overall trend suggests increasing efficiency in converting operating profit into net profit as margins improved.
Return on Equity (ROE)
ROE mirrored the trends observed in the profit margins, decreasing from 18.56% in April 2022 to 12.83% in December 2023. A subsequent increase brought ROE to 13.19% in March 2025, followed by a slight decrease to 12.88% in September 2025. This indicates a fluctuating ability to generate profit from shareholder investments.
Return on Assets (ROA)
ROA exhibited a similar pattern, declining from 8.20% in April 2022 to 6.07% in December 2023. It then rose to 6.58% in March 2025, before decreasing to 6.38% in September 2025. The trend suggests a fluctuating efficiency in utilizing assets to generate earnings.

In summary, the period began with a consistent decline in profitability ratios. While a recovery was observed from mid-2023 through early 2025, the most recent quarterly results suggest a potential stabilization or slight reversal of this positive trend. Further monitoring is warranted to determine if this represents a temporary fluctuation or a more significant shift in performance.


Return on Sales


Return on Investment


Gross Profit Margin

Thermo Fisher Scientific Inc., gross profit margin calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 27, 2025 Jun 28, 2025 Mar 29, 2025 Dec 31, 2024 Sep 28, 2024 Jun 29, 2024 Mar 30, 2024 Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022
Selected Financial Data (US$ in millions)
Gross profit
Revenues
Profitability Ratio
Gross profit margin1
Benchmarks
Gross Profit Margin, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).

1 Q4 2025 Calculation
Gross profit margin = 100 × (Gross profitQ4 2025 + Gross profitQ3 2025 + Gross profitQ2 2025 + Gross profitQ1 2025) ÷ (RevenuesQ4 2025 + RevenuesQ3 2025 + RevenuesQ2 2025 + RevenuesQ1 2025)
= 100 × ( + + + ) ÷ ( + + + ) =

2 Click competitor name to see calculations.


The gross profit margin exhibited a clear downward trend from April 2022 through December 2022, followed by a period of relative stabilization and eventual increase through December 2025. Initial values were relatively high, but progressively decreased over the analyzed period before showing signs of recovery.

Initial Decline (Apr 2, 2022 – Dec 31, 2022)
The gross profit margin began at 48.37% in April 2022 and consistently declined each quarter, reaching a low of 42.24% by December 2022. This represents a decrease of approximately 6.13 percentage points over eight quarters. This period suggests increasing costs of goods sold relative to revenue.
Stabilization and Gradual Recovery (Apr 1, 2023 – Dec 31, 2024)
From April 2023 to December 2024, the gross profit margin remained relatively stable, fluctuating between 39.75% and 41.28%. While some quarterly variation existed, the overall trend was one of limited change. This suggests that cost management efforts may have begun to offset the previous declines, or that revenue and cost increases were proportionally aligned.
Recent Improvement (Mar 29, 2025 – Dec 31, 2025)
The final four quarters analyzed demonstrate a modest increase in the gross profit margin. It rose from 41.34% in March 2025 to 40.93% in December 2025. While not a substantial increase, this indicates a potential positive shift in the company’s ability to control costs or increase pricing power.
Gross Profit and Revenue Relationship
Throughout the period, gross profit and revenues generally moved in the same direction, but the rate of change differed. Revenue decreased from $11,818 million to $10,345 million between April 2022 and April 2023, while the gross profit margin decreased more significantly. The subsequent revenue growth from $10,364 million in March 2025 to $12,215 million in December 2025 was accompanied by a smaller increase in the gross profit margin, suggesting that revenue growth is not directly translating into proportional margin expansion.

Overall, the gross profit margin experienced a period of decline followed by stabilization and a slight recovery. Continued monitoring of this metric, alongside detailed analysis of cost of goods sold, is recommended to understand the underlying drivers of these trends.


Operating Profit Margin

Thermo Fisher Scientific Inc., operating profit margin calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 27, 2025 Jun 28, 2025 Mar 29, 2025 Dec 31, 2024 Sep 28, 2024 Jun 29, 2024 Mar 30, 2024 Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022
Selected Financial Data (US$ in millions)
Operating income
Revenues
Profitability Ratio
Operating profit margin1
Benchmarks
Operating Profit Margin, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).

1 Q4 2025 Calculation
Operating profit margin = 100 × (Operating incomeQ4 2025 + Operating incomeQ3 2025 + Operating incomeQ2 2025 + Operating incomeQ1 2025) ÷ (RevenuesQ4 2025 + RevenuesQ3 2025 + RevenuesQ2 2025 + RevenuesQ1 2025)
= 100 × ( + + + ) ÷ ( + + + ) =

2 Click competitor name to see calculations.


The operating profit margin exhibited a generally declining trend from April 2022 through July 2023, followed by a period of stabilization and modest growth through December 2025. Initial values were relatively high, but experienced a consistent decrease before beginning to recover.

Overall Trend
The operating profit margin began at 23.83% in April 2022 and decreased to a low of 15.42% in July 2023. From this point, the margin demonstrated a recovery, increasing to 17.38% by December 2025. While fluctuations occurred, the overall trajectory suggests a period of margin compression followed by stabilization and improvement.
Initial Decline (Apr 2022 - Jul 2023)
A consistent decline in the operating profit margin was observed over the first six quarters. The margin decreased from 23.83% to 22.51%, 20.54%, 18.69%, 16.29%, and finally reaching 15.42%. This suggests increasing cost pressures or decreasing pricing power during this period.
Stabilization and Recovery (Jul 2023 - Dec 2025)
Following the low in July 2023, the operating profit margin showed signs of stabilization and gradual recovery. The margin increased to 15.81% in September 2023, 16.00% in December 2023, 16.38% in March 2024, and 17.01% in June 2024. This upward trend continued, reaching 17.11% in December 2024 and culminating in 17.38% by December 2025. The recovery, while present, was relatively modest.
Quarterly Fluctuations
Despite the overall trends, some quarterly fluctuations were present. For example, a slight decrease was noted from June 2024 (17.01%) to September 2024 (16.93%), followed by a recovery. These fluctuations suggest potential seasonality or short-term impacts from specific business events.
Relationship to Revenue
While the operating profit margin was analyzed in isolation, it is important to note that revenues also experienced fluctuations. Revenues decreased from $11,818 million in April 2022 to $10,574 million in September 2023, before increasing to $12,215 million in December 2025. The interplay between revenue and operating income is crucial for a complete understanding of the company’s financial performance.

Net Profit Margin

Thermo Fisher Scientific Inc., net profit margin calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 27, 2025 Jun 28, 2025 Mar 29, 2025 Dec 31, 2024 Sep 28, 2024 Jun 29, 2024 Mar 30, 2024 Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022
Selected Financial Data (US$ in millions)
Net income attributable to Thermo Fisher Scientific Inc.
Revenues
Profitability Ratio
Net profit margin1
Benchmarks
Net Profit Margin, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).

1 Q4 2025 Calculation
Net profit margin = 100 × (Net income attributable to Thermo Fisher Scientific Inc.Q4 2025 + Net income attributable to Thermo Fisher Scientific Inc.Q3 2025 + Net income attributable to Thermo Fisher Scientific Inc.Q2 2025 + Net income attributable to Thermo Fisher Scientific Inc.Q1 2025) ÷ (RevenuesQ4 2025 + RevenuesQ3 2025 + RevenuesQ2 2025 + RevenuesQ1 2025)
= 100 × ( + + + ) ÷ ( + + + ) =

2 Click competitor name to see calculations.


The net profit margin exhibited fluctuations over the analyzed period, spanning from April 2022 to December 2025. An initial decline is observed from the first quarter of the period through the final quarter of 2022, followed by a period of relative stability and subsequent increases towards the end of the observation window.

Initial Decline (Apr 2, 2022 – Dec 31, 2022)
The net profit margin began at 18.49% in April 2022 and decreased consistently over the subsequent three quarters, reaching 15.47% by December 2022. This represents a cumulative decrease of approximately 3.02 percentage points within this timeframe. This decline occurred alongside a slight fluctuation in revenues.
Stabilization and Gradual Increase (Apr 1, 2023 – Dec 31, 2024)
Following the decline, the net profit margin stabilized in the first quarter of 2023 at 13.75%. A gradual upward trend is then apparent, with the margin increasing to 14.77% by December 2024. This represents an overall increase of approximately 1.02 percentage points. Revenue figures demonstrate a general increase during this period.
Continued Improvement (Mar 29, 2025 – Dec 31, 2025)
The net profit margin continued to improve in the final year of the analyzed period, reaching 15.05% by December 2025. The margin peaked at 15.23% in June 2025. This final phase demonstrates continued profitability improvements, coinciding with a significant increase in revenues to 12,215 US$ in millions.

Overall, the trend suggests a period of initial margin compression followed by a recovery and sustained improvement. The latter portion of the period demonstrates a positive correlation between revenue growth and net profit margin expansion, indicating increasing operational efficiency or pricing power.


Return on Equity (ROE)

Thermo Fisher Scientific Inc., ROE calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 27, 2025 Jun 28, 2025 Mar 29, 2025 Dec 31, 2024 Sep 28, 2024 Jun 29, 2024 Mar 30, 2024 Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022
Selected Financial Data (US$ in millions)
Net income attributable to Thermo Fisher Scientific Inc.
Total Thermo Fisher Scientific Inc. shareholders’ equity
Profitability Ratio
ROE1
Benchmarks
ROE, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).

1 Q4 2025 Calculation
ROE = 100 × (Net income attributable to Thermo Fisher Scientific Inc.Q4 2025 + Net income attributable to Thermo Fisher Scientific Inc.Q3 2025 + Net income attributable to Thermo Fisher Scientific Inc.Q2 2025 + Net income attributable to Thermo Fisher Scientific Inc.Q1 2025) ÷ Total Thermo Fisher Scientific Inc. shareholders’ equity
= 100 × ( + + + ) ÷ =

2 Click competitor name to see calculations.


The Return on Equity (ROE) for the analyzed period demonstrates a general declining trend, although with some fluctuations. Initial values indicate a relatively strong ROE, which subsequently moderates over the observed timeframe. A detailed examination of the ROE alongside its contributing factors reveals specific patterns.

Overall Trend
The ROE began at 18.56% in April 2022 and generally decreased to 12.55% by December 2025. This represents a substantial relative decline over the period. While there are quarterly variations, the overall trajectory is downward.
Initial Decline (2022-2023)
A consistent decrease in ROE is evident from April 2022 through December 2023, moving from 18.56% to 12.83%. This decline coincides with a period of fluctuating net income and consistently increasing shareholders’ equity. The increase in equity, while positive for overall financial structure, appears to be diluting the return to shareholders during this period.
Stabilization and Fluctuations (2024-2025)
From April 2024 through December 2025, the ROE exhibits more moderate fluctuations, generally remaining within a range of 12.52% to 13.26%. While not demonstrating significant recovery, the rate of decline slows. The ROE reached 12.52% in September 2024, representing a low point in the observed period, before increasing to 12.55% by December 2025.
Net Income and Equity Relationship
The observed ROE trend is influenced by the relationship between net income and shareholders’ equity. While net income experiences quarterly variations, it does not demonstrate a consistent upward trend that would offset the continuous growth in shareholders’ equity. The consistent increase in equity, driven by retained earnings and potentially other factors, contributes to the observed decline in ROE, as the same level of net income is distributed across a larger equity base.

In summary, the ROE demonstrates a clear downward trend over the analyzed period. This trend is primarily attributable to the consistent growth in shareholders’ equity outpacing the growth in net income. The period from 2024 to 2025 shows a stabilization of the ROE, but it remains significantly lower than the initial values observed in 2022.


Return on Assets (ROA)

Thermo Fisher Scientific Inc., ROA calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 27, 2025 Jun 28, 2025 Mar 29, 2025 Dec 31, 2024 Sep 28, 2024 Jun 29, 2024 Mar 30, 2024 Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022
Selected Financial Data (US$ in millions)
Net income attributable to Thermo Fisher Scientific Inc.
Total assets
Profitability Ratio
ROA1
Benchmarks
ROA, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).

1 Q4 2025 Calculation
ROA = 100 × (Net income attributable to Thermo Fisher Scientific Inc.Q4 2025 + Net income attributable to Thermo Fisher Scientific Inc.Q3 2025 + Net income attributable to Thermo Fisher Scientific Inc.Q2 2025 + Net income attributable to Thermo Fisher Scientific Inc.Q1 2025) ÷ Total assets
= 100 × ( + + + ) ÷ =

2 Click competitor name to see calculations.


The Return on Assets (ROA) exhibited a generally declining trend over the observed period, although with some fluctuations. Initial values were relatively strong, followed by a period of stabilization and then a modest recovery towards the end of the timeframe.

Initial Performance (Apr 2, 2022 – Dec 31, 2022)
The ROA began at 8.20% in April 2022 and remained relatively stable at 8.21% in July 2022. A gradual decline was then observed, reaching 7.77% in October 2022 and further decreasing to 7.15% by the end of the year. This initial period suggests a slight erosion in the efficiency of asset utilization in generating profits.
Subsequent Decline and Stabilization (Apr 1, 2023 – Dec 31, 2023)
The downward trend continued into the first half of 2023, with the ROA falling to 6.36% in April 2023 and 6.08% in July 2023. The ratio showed limited movement between 6.08% and 6.12% for the remainder of 2023, indicating a period of stabilization at a lower level of profitability relative to asset base.
Recent Fluctuations and Recovery (Mar 30, 2024 – Dec 31, 2025)
A slight increase in ROA was observed in March 2024, reaching 6.21%, followed by 6.32% in June 2024. The ratio then decreased to 6.11% in September 2024 before rising to 6.51% in December 2024. This was followed by a slight decrease to 6.58% in March 2025, 6.50% in June 2025, and 6.38% in September 2025. The ROA concluded the period at 6.08% in December 2025. This final period demonstrates some volatility, but ultimately ends at a level comparable to the mid-2023 values.
Overall Trend
Considering the entire period, the ROA experienced a net decrease. While there were periods of stabilization and minor recovery, the ratio did not return to the levels observed in the initial months of the analyzed timeframe. This suggests potential challenges in maintaining profitability relative to the company’s asset base over the long term.